OUTSIDE REVIEWS OF DRUG SAFETY AND EFFICACY DATA
This article was originally published in The Tan Sheet
Executive Summary
OUTSIDE REVIEWS OF DRUG SAFETY AND EFFICACY DATA is an issue that is likely to be revisited in the upcoming Congress as the newly dominant Republican party reasserts its anti-regulatory agenda. Another GOP priority is emphasizing safety over efficacy in evaluating new products and placing more reliance on post- approval data. The European system of drug evaluation is a likely model for consideration, Hill staffers said.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning